TUESDAY, April 15, 2025 (HealthDay News) — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes prescribed weight-lowering medications (WLMs), according to a study published online April 15 in the Annals of Internal Medicine. John W. Ostrominski, M.D., from Brigham and Women’s Hospital […]
The post Tirzepatide Dispensations Increased Rapidly After Approval first appeared on Physician’s Weekly.
